Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel, Switzerland) November 5, 2024 Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al. 4 citations
Psychedelics are reemerging as potential treatments for substance use disorders (SUDs), including alcohol and opioid use disorders. Early mid-20th century anecdotal reports and pilot studies suggested these compounds could be effective, but legal restrictions and stigma halted research. With rising rates of SUDs and other mental health conditions, researchers are again investigating psychedelics for their unique pharmacological targets and holistic treatment potential. This review examines emerging evidence for treating SUDs with psilocybin, ketamine, LSD, MDMA, ayahuasca, ibogaine, and peyote.